Recombinant anti-BDCA2 humanized monoclonal antibody (Sansheng Guojian)

重组抗BDCA2人源化单克隆抗体（三生国健）

Report date: 2024/10/29 14:12:17

Base Information

Drug NameRecombinant anti-BDCA2 humanized monoclonal antibody (Sansheng Guojian)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-C-Type lectin domain family 4 member C
TargetsC-Type lectin domain family 4 member C
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A